medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24303229; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

1 ¹⁸F-NaF Uptake on Vascular PET Imaging in Symptomatic versus Asymptomatic

2 Atherosclerotic Disease: a Meta-Analysis

- 3 Bhakta S¹, Chowdhury MM², Tarkin JM³, Rudd JHF³, Warburton EA¹, Evans NR¹
- 4
- ⁵ ¹Department of Clinical Neurosciences, University of Cambridge, Cambridge. CB2 0QQ
- ⁶ ²Department of Vascular Surgery, University of Cambridge, Cambridge. CB2 0QQ
- ⁷ ³Division of Cardiovascular Medicine, University of Cambridge, Cambridge. CB2 0QQ
- 8
- 9 Corresponding author:
- 10 Nicholas Evans
- 11 R3 Clinical Neurosciences
- 12 Addenbrooke's Hospital
- 13 Cambridge
- 14 CB2 0QQ
- 15
- 16 Email: ne214@cam.ac.uk
- 17 Twitter: @nr_evans
- 18
- 19 Word count: 6634
- 20

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 Abstract

22

23 Introduction

24

25 ¹⁸F-sodium fluoride (NaF) positron-emission tomography (PET) is increasingly being used to 26 measure microcalcification in atherosclerotic disease in vivo. Correlations have been drawn 27 between sodium fluoride uptake and the presence of high-risk plaque features, as well as its 28 association with clinical atherosclerotic sequelae. The aim of this review was to perform a 29 meta-analysis of NaF uptake on PET imaging and its relation to symptomatic and 30 asymptomatic disease. 31 32 Methods

33

34 A systematic review was performed according to PRISMA guidelines, via searching the 35 MEDLINE database up to August 2023. The search strategy included the terms "NaF", "PET" 36 and "plaque", and all studies were included where there was data listed regarding the 37 degree of microcalcification, as measured by ¹⁸F-NaF uptake in symptomatic and 38 asymptomatic atherosclerotic plaques. Analysis involved calculating standardized mean 39 differences between uptake values and comparison using a random-effects model. 40 41 **Results** 42 43 A total of 15 articles, involving 423 participants, were included in the meta-analysis. Comparing ¹⁸F-NaF uptake in symptomatic vs asymptomatic atherosclerotic plaques, a 44 45 standardized mean difference of 0.42 (95% CI 0.29-0.56; p<0.001, $I^2 = 54.1\%$) was noted for

46 those studies comparing symptomatic and asymptomatic plaques in the same participant,

- 47 with no significant change in effect based on arterial territory studied ($Q_M = 5.02$, p = 0.08).
- 48 In those studies where data was included from participants with and without symptomatic

49 disease, the standardized mean difference between symptomatic and asymptomatic

50 plaques was 0.44 (95% CI 0.03-0.85, p=0.037, $I^2 = 40.4\%$). All studies including asymptomatic

- 51 participants were investigating carotid disease.
- 52

53 **Conclusions**

- 54
- PET imaging using ¹⁸F-NaF can detect differences in microcalcification between symptomatic 55
- 56 and asymptomatic atherosclerotic plaques within and between individuals, and is a marker
- of symptomatic disease. The standardization of ¹⁸F-NaF PET imaging protocols, and its future 57
- 58 use as a risk stratification tool or outcome measure, requires further study.
- 59

60 **Non-standard Abbreviations and Acronyms**

61

62 MDS – most diseased segment

- 63 NaF – sodium fluoride
- 64 ROI – region of interest
- 65 SUV - standardized uptake value
- TBR tissue-to-background ratio 66
- 67 TBRmax – maximum tissue-to-background ratio from the region of interest

68 Introduction

69

70 Atherosclerosis is a systemic chronic arterial disease¹, involving the accumulation of lipids 71 and inflammatory cells² to form foci of disease, termed 'plaques', at the vessel wall. It is the 72 cause of over one third of all deaths³, through resulting diseases such as myocardial 73 infarction, ischemic stroke, and critical limb threatening ischemia. In some patients, minor 74 or less severe clinical symptoms may be a marker of higher risk for progressing to more severe clinical disease, such as stable angina preceding myocardial infarction^{4,5}, or transient 75 76 ischemic attack, conferring a higher risk of ischemic stroke in the short term^{6,7}. 77

Plaques may have heterogenous appearances⁸, with certain plaque features indicating a 78 higher risk of rupture and subsequent clinical sequelae^{8,9}. These high-risk features include 79 the presence of a lipid-rich necrotic core¹⁰, intraplaque hemorrhage¹¹, a thin or ruptured 80 fibrous cap¹², and the presence of microcalcification¹³. The mechanisms determining the 81 82 transition from a low-risk ("stable") to a high-risk ("unstable") plaque and vice versa are 83 incompletely understood^{14,15}, but microcalcification has been recognized as a potential 84 cause for acute plaque rupture, through mechanical destabilization of the fibrous cap of the 85 plaque¹⁶, as well as causing an increased inflammatory response within the plaque¹⁷, leading to enzymatic destabilization of the plaque¹⁸. Microcalcifications are calcium deposits of 86 <50µm in diameter, which is below the spatial resolution of commonly-used clinical vascular 87 imaging techniques¹⁹, such as computed tomography (CT) or magnetic resonance imaging 88 89 (MRI).

90

91 Positron emission tomography (PET) is a nuclear imaging technique used in vascular imaging 92 due to its high sensitivity to detect low concentrations of radiolabeled ligands (termed 93 "tracers"), which can be directed to detect the presence of a specific target or process²⁰. 94 Sodium fluoride (NaF), labelled with fluorine-18, has been validated as a tracer for the 95 identification of microcalcification in vascular imaging²¹.

96

97 NaF adsorbs to the surface of hydroxyapatite within the body²², with hydroxyapatite being 98 the most common calcium-containing crystal structure in atherosclerotic plaques in vivo^{23,24}. 99 Fluorine exchanges with hydroxyl groups on the surface of these crystals, while there is

100	substantially less tracer uptake deeper within the crystal structure of the molecule ²² .
101	Calcium deposits with an increased surface area therefore have increased fluoride ion
102	uptake over the uptake durations used in clinical PET scanning ^{22,25} . Using NaF, this process
103	of hydroxyl-ion substitution can be used to detect microcalcifications via PET imaging. Due
104	to their high surface area to volume ratio, microcalcifications will demonstrate higher
105	uptake on PET compared to areas with no microcalcification, or those with larger deposits of
106	calcium ("macrocalcification") ²⁶⁻²⁸ . NaF-PET can be preferred for vascular imaging compared
107	to other PET imaging techniques for visualizing high-risk plaques due to issues, such as 'spill-
108	over artefact' when using fluorodeoxyglucose (FDG)-PET in cardiac imaging.
109	
110	There is an increasing body of literature demonstrating the use of NaF-PET for vascular
111	imaging in atherosclerosis ²⁹ , and specifically, in symptomatic disease. This meta-analysis
112	focuses on the role of NaF-PET imaging to differentiate between symptomatic versus
113	asymptomatic atherosclerotic disease.
114	
115	<u>Methods</u>
116	
117	Protocol, Search Strategy and Selection Criteria
118	
119	Details for the protocol were registered on PROSPERO ³⁰ . The selection process and
120	reporting items were based on the preferred reporting items for systematic reviews and
121	meta-analysis (PRISMA) flow diagram and checklist ³¹ . The primary outcome was to
122	determine differences in NaF tracer uptake between symptomatic and asymptomatic
123	atherosclerotic plaques. A search strategy was formulated using Embase and Medline All via
124	Ovid (Figure 1). Additionally, a manual search was performed to identify relevant records
125	through reference searches. Duplicate records were removed, and the retrieved records
126	were checked for inclusion and exclusion criteria.

127

128 Studies were eligible for inclusion if they investigated the association between NaF uptake 129 and symptomatic and asymptomatic atherosclerotic plaques, where symptomatic plaques

130 were those that were associated with a recent clinical vascular event, including, but not

131 limited to, stroke or myocardial infarction, while asymptomatic plaques were those not

- 132 associated with a recent clinical vascular event. Studies were excluded if animal data was
- 133 used, non-atherosclerotic disease was investigated, or if the study did not provide details
- 134 regarding the type or location of symptomatic disease.
- 135

136 Data Selection, Extraction and Quality Assessment

- 137
- 138 Data were extracted by one study investigator (S. B.) and checked by another researcher (N.

139 R. E.), from the included records, using a standardized electronic data collection form.

140 Discrepancies were resolved by re-extraction or by third-party adjudication (E. A. W.) as

141 required. Retrieved characteristics from the studies included, but was not limited to, the

142 number of subjects, patient population, targeted vascular territory, dose of NaF injected,

143 uptake time, imaging protocols, primary endpoint measures for PET/CT and main findings,

which were tabulated as per published guidance³². The ROBINS-E tool³³ was used to assess 144

145 the quality of the studies included in this review (Supplementary Figure 1).

146

147 Statistical Analysis

148

149 The mean and associated standard deviation (SD), or the median and the associated 150 interquartile range (IQR) of the measurement of NaF signal were extracted from the 151 included studies. Extracted median and IQR data was converted into mean and SD data in 152 order to calculate a unified outcome³⁴. In studies where multiple measures of NaF signal 153 were listed, the value corresponding to the TBR related to the maximum SUV value (TBR_{max}) 154 was taken. The absolute difference between the populations when NaF signal is measured 155 using SUV versus TBR is minor, given the low blood pool activity of NaF following an 156 appropriate uptake time¹⁹.

157

158 Studies were classified by their included participants – those with only symptomatic 159 participants, or those also including an asymptomatic control population. The effect 160 estimates from each study were pooled using the inverse-variance weighted method, and 161 random effects models were used for meta-analysis. I^2 statistics were calculated to 162 determine the variability in effect estimate due to between-study heterogeneity. Meta-163 analyses were performed where there were two or more studies using the same type of

164 included population. Standardized mean differences were calculated due to the variability in165 reporting outcomes used in the included studies.

166

167 Funnel plots (Figures 2 and 3) were used to visually assess the symmetry of the studies

about the mean effect size, to identify any publication bias. Two-tailed tests were used, and

169 a *p*-value of 0.05 was taken as the limit of statistical significance. Statistical analyses were

170 performed using the *metafor*³⁵ and *metamedian*³⁶ packages, using R Statistical Software

171 (v4.3.1, R Core Team 2023).

172

173 Subgroup analysis was performed between the different arterial territories assessed in the

174 included studies to generate standardized mean difference measurements for symptomatic

175 atherosclerotic plaques compared with asymptomatic plaques, and to determine any

176 statistical differences in NaF uptake between different arterial territories.

- 177
- 178 <u>Results</u>
- 179

180 Included Studies

181

182 A total of 966 titles were initially identified from the search (Figure 4)³⁷. Manual de-183 duplication of results was performed, and the remaining 733 records underwent manual 184 screening of the titles and abstracts³⁸. Of those, 636 were excluded as not meeting the 185 inclusion criteria. 97 articles were therefore sought for retrieval. Five articles were not 186 available for analysis and 92 articles were therefore assessed for eligibility through full-text 187 review. Of these, 77 were excluded, 53 due to not reporting outcomes related to 188 symptomatic atherosclerotic disease, 15 due to no documented comparison between 189 symptomatic and asymptomatic disease, eight due to discussion of imaging protocols and 190 quality assessment and one due to reporting outcome measures insufficient for meta-191 analysis. The remaining 15 articles were included in the meta-analysis, and form the study 192 population analyzed. A summary of study details is shown in Tables 1 and 2, dichotomized 193 based on the comparator of symptomatic disease used in each study. 194

195	Comparative intra-individual ¹⁸ F-NaF tracer uptake between symptomatic and
196	asymptomatic atherosclerotic disease
197	
198	Ten studies, including 352 participants, reported data in participants comparing NaF uptake
199	in the symptomatic atherosclerotic plaque compared to asymptomatic plaques within the
200	same participant's vascular territory being observed, including data for 317 symptomatic,
201	and 336 asymptomatic plaques (Table 1).
202	
203	Pooled comparisons of these studies demonstrated a significantly higher uptake in
204	symptomatic lesions compared to asymptomatic plaques (standardized mean difference
205	0.42, 95% CI 0.29-0.56, <i>p</i> <0.001, Figure 5). Subgroup analysis to compare results from
206	different arterial territories showed no significant difference in this relationship based on
207	the site of the symptomatic plaque (Q_M = 5.02, p = 0.08). Significant heterogeneity was
208	noted between the studies (Q = 19.89, I^2 = 54.1%, p = 0.019).
209	
210	Comparative NaF tracer uptake in symptomatic and asymptomatic atherosclerotic plaques
211	where a healthy control population was included
212	
213	Five studies, including 71 participants, reported data in participants comparing NaF uptake
214	in the symptomatic atherosclerotic plaque compared to asymptomatic plaques, pooling data
215	from asymptomatic disease within the same symptomatic individual and plaques from
216	asymptomatic healthy controls, including data for 47 symptomatic, and 63 asymptomatic
217	plaques (Table 2).
218	
219	Analysis of the pooled data from these studies demonstrated a significantly higher NaF
220	uptake in symptomatic atherosclerotic lesions compared to asymptomatic lesions, present
221	in the same individuals, or in healthy controls (standardized mean difference 0.44, 95% CI
222	0.03-0.85, <i>p</i> = 0.037, Figure 6). All studies analyzed assessed atherosclerotic disease within
223	the carotid arteries, and subgroup analysis for differences between different arterial
224	territories was therefore not conducted. There was no significant heterogeneity between
225	studies included in this analysis (Q = 6.37 , $I^2 = 40.4\%$, p = 0.17).
226	

227 Discussion

228

229 These results demonstrate the utility of NaF-PET, combined with CT or MRI, to differentiate 230 between symptomatic and asymptomatic atherosclerotic disease in a number of different 231 vascular territories. Studies have also demonstrated a correlation between NaF uptake and 232 high-risk morphological features on MRI, such as the presence of a lipid-rich necrotic core, 233 or intraplaque haemorrhage³⁹. In addition, there is emerging evidence of a prognostic link 234 between NaF signal on PET and the risk of recurrent disease⁴⁰, where coronary NaF imaging 235 had the ability to predict myocardial infarction and cardiovascular death. 236

237 As noted in **Tables 1 and 2**, there are a range of different doses of NaF used, along with a 238 non-standardized uptake time, blood pool measurement for TBR calculations, and outcome 239 measurement. Irkle et al²⁵ demonstrated an optimum uptake time of around 60 minutes, 240 based on *in vitro* and *in vivo* data. However, NaF-PET lacks a consensus on best practice, in 241 contrast to vascular FDG-PET imaging, following the 2005 position paper from the European 242 Association of Nuclear Medicine⁴¹. Having a standardized methodology for performing and 243 analyzing vascular NaF imaging would allow increased comparability and reproducibility 244 between studies.

245

246 There was also significant heterogeneity in the included studies between the time of 247 symptom onset and imaging being performed. There is little data concerning the temporal 248 changes in microcalcification and NaF uptake following an acute atherosclerotic event, and 249 further information on the optimum time period for imaging microcalcification in relation to 250 symptomatic disease could further standardize imaging protocols and improve robustness 251 of outcomes measured using NaF-PET as a surrogate marker.

252

253 In atherosclerosis, PET has been demonstrated to have a high sensitivity for the target 254 pathophysiology and can be combined with other imaging modalities to provide additional 255 utility, such as in combination with CT and CT angiography to assess for stenotic disease⁴² 256 and calcium scores in the coronary vasculature⁴³, or with MRI, to identify high risk 257 appearances as discussed above⁴⁴. In vascular imaging, NaF may be superior to FDG as it 258 may have a superior ability to discriminate between symptomatic and asymptomatic disease

in high-risk individuals⁴⁵. In addition, NaF does not require fasting prior to the uptake
period, and can be used with a shorter uptake time compared to FDG-PET^{25,41}. NaF is also
less susceptible to spill-over artefact, such as from the myocardium, which can limit FDGbased PET imaging of the arteries⁴⁵. However, the cost, radiation exposure and uptake and
scanning time mean the role of PET imaging in routine clinical assessment of atherosclerotic
disease is currently limited.

265

266 Microcalcification is known to confer an increased risk of plaque rupture through 267 enzymatic¹⁸ and mechanical¹⁷ destabilization of the plaque surface. Therefore, targeting this 268 process may reduce the risk of early recurrence following symptomatic atherosclerotic 269 disease. NaF-PET can be utilized to assess responses to clinical interventions, given its 270 accuracy and sensitivity in determining differences in the presence of microcalcification in 271 vivo⁴⁶. Additionally, the process by which microcalcification evolves into macrocalcification, 272 which is thought to be protective for the atherosclerotic plaque, is poorly defined and 273 understood⁴⁷. Temporal evaluation of the microcalcification-macrocalcification process 274 through NaF-PET/CT could shed more light on the factors which confer a greater or lesser 275 degree of risk with calcification in atherosclerosis. In addition, NaF imaging could potentially 276 have a role in risk stratification in patients where there is uncertainty about the risk of 277 recurrent stroke or the need for surgical intervention, which is particularly relevant for 278 those with moderate 50-69% stenoses.

279

280 <u>Conclusion</u>

281

282 Our findings support vascular NaF-PET imaging as a reliable method for assessment of 283 atherosclerotic disease that is able to help differentiate between symptomatic/vulnerable 284 plaques and asymptomatic/stable plaques. The majority of data involves analysis of the 285 carotid or coronary circulation, but NaF-PET imaging is also a viable imaging technique in 286 other arterial territories. There is a potential future role of NaF-PET in clinical 287 atherosclerosis imaging and providing surrogate markers of impact in interventional trials, 288 but harmonization of imaging protocols including outcome measures, injected doses and 289 uptake times is required to ensure comparability between studies.

290

291 Funding

- 292
- 293 SB is supported by a Research Training Fellowship from The Dunhill Medical Trust
- 294 [JBGS22\20]. The ICARUSS study was supported as part of a Research Training Fellowship
- 295 awarded to NRE by The Dunhill Medical Trust [RTF44/0114], and by the NIHR Cambridge
- 296 Biomedical Research Centre (NIHR203312). MC is supported by a BHF Career Development
- 297 Fellowship and the NIHR. JMT is supported by a Wellcome Trust Clinical Research Career
- 298 Development Fellowship (211100/Z/18/Z) and the Cambridge BHF Centre for Research
- 299 Excellence (18/1/34212). JHFR is part-supported by the NIHR Cambridge Biomedical
- 300 Research Centre, the British Heart Foundation, HEFCE, the EPSRC and the Wellcome Trust.
- 301 NRE is supported by a Stroke Association Senior Clinical Lectureship [SA-SCL-MED-
- 302 22\100006].
- 303
- 304 Disclosures
- 305
- 306 None

- Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgözoğlu L, Lewis EF. Atherosclerosis. *Nature Reviews Disease Primers*. 2019;5:56. doi: 10.1038/s41572-019-0106-z
- Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I,
 Vandenbroeck K, Benito-Vicente A, Martín C. Pathophysiology of Atherosclerosis. *Int J Mol Sci.* 2022;23. doi: 10.3390/ijms23063346
- Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, et al. European Society of Cardiology: cardiovascular disease statistics 2021. *European Heart Journal*. 2022;43:716-799. doi: 10.1093/eurheartj/ehab892
- Eisen A, Bhatt DL, Steg PG, Eagle KA, Goto S, Guo J, Smith SC, Ohman EM, Scirica BM.
 Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery
 Disease: Insights From the Reduction of Atherothrombosis for Continued Health
 (REACH) Registry. J Am Heart Assoc. 2016;5. doi: 10.1161/jaha.116.004080
- Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. *Am J Cardiol*. 1972;29:154-163. doi: 10.1016/0002-9149(72)90624-8
- Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. *Neurology*. 2005;64:817-820. doi: 10.1212/01.Wnl.0000152985.32732.Ee
- Johansson E, Cuadrado-Godia E, Hayden D, Bjellerup J, Ois A, Roquer J, Wester P,
 Kelly PJ. Recurrent stroke in symptomatic carotid stenosis awaiting revascularization:
 A pooled analysis. *Neurology*. 2016;86:498-504. doi:
 10.1212/wnl.0000000002354
- Insull W. The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment. *The American Journal of Medicine*. 2009;122:S3-S14. doi: <u>https://doi.org/10.1016/j.amjmed.2008.10.013</u>
- Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of Vulnerable/Unstable Plaque. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2010;30:1282-1292. doi: 10.1161/ATVBAHA.108.179739
- 10. Fleg JL, Stone GW, Fayad ZA, Granada JF, Hatsukami TS, Kolodgie FD, Ohayon J, Pettigrew R, Sabatine MS, Tearney GJ, et al. Detection of high-risk atherosclerotic

plaque: report of the NHLBI Working Group on current status and future directions. *JACC Cardiovasc Imaging*. 2012;5:941-955. doi: 10.1016/j.jcmg.2012.07.007

- Deng F, Mu C, Yang L, Li H, Xiang X, Li K, Yang Q. Carotid plaque magnetic resonance imaging and recurrent stroke risk: A systematic review and meta-analysis. *Medicine* (*Baltimore*). 2020;99:e19377. doi: 10.1097/md.00000000019377
- Redgrave JN, Gallagher P, Lovett JK, Rothwell PM. Critical cap thickness and rupture in symptomatic carotid plaques: the oxford plaque study. *Stroke*. 2008;39:1722-1729. doi: 10.1161/strokeaha.107.507988
- Vancheri F, Longo G, Vancheri S, Danial JSH, Henein MY. Coronary Artery Microcalcification: Imaging and Clinical Implications. *Diagnostics (Basel)*. 2019;9. doi: 10.3390/diagnostics9040125
- 14. Fox KAA, Metra M, Morais J, Atar D. The myth of 'stable' coronary artery disease. *Nature Reviews Cardiology*. 2020;17:9-21. doi: 10.1038/s41569-019-0233-y
- 15. Akers EJ, Nicholls SJ, Di Bartolo BA. Plaque Calcification. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2019;39:1902-1910. doi: 10.1161/ATVBAHA.119.311574
- Shi X, Gao J, Lv Q, Cai H, Wang F, Ye R, Liu X. Calcification in Atherosclerotic Plaque Vulnerability: Friend or Foe? *Frontiers in Physiology*. 2020;11. doi: 10.3389/fphys.2020.00056
- Kawtharany L, Bessueille L, Issa H, Hamade E, Zibara K, Magne D. Inflammation and Microcalcification: A Never-Ending Vicious Cycle in Atherosclerosis? *Journal of Vascular Research*. 2022;59:137-150. doi: 10.1159/000521161
- Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. *J Intern Med*.
 2015;278:483-493. doi: 10.1111/joim.12406
- Tzolos E, Dweck MR. ¹⁸F-Sodium Fluoride (¹⁸F-NaF) for Imaging Microcalcification Activity in the Cardiovascular System. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2020;40:1620-1626. doi: doi:10.1161/ATVBAHA.120.313785
- Sriranjan RS, Tarkin JM, Evans NR, Le EPV, Chowdhury MM, Rudd JHF. Atherosclerosis imaging using PET: Insights and applications. *British Journal of Pharmacology*.
 2021;178:2186-2203. doi: <u>https://doi.org/10.1111/bph.14868</u>

- Høilund-Carlsen PF, Sturek M, Alavi A, Gerke O. Atherosclerosis imaging with (18)Fsodium fluoride PET: state-of-the-art review. *Eur J Nucl Med Mol Imaging*. 2020;47:1538-1551. doi: 10.1007/s00259-019-04603-1
- 22. Blau M, Ganatra R, Bender MA. 18F-fluoride for bone imaging. *Seminars in Nuclear Medicine*. 1972;2:31-37. doi: https://doi.org/10.1016/S0001-2998(72)80005-9
- Schmid K, McSharry WO, Pameijer CH, Binette JP. Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta. *Atherosclerosis*. 1980;37:199-210. doi: <u>https://doi.org/10.1016/0021-9150(80)90005-2</u>
- Bischetti S, Scimeca M, Bonanno E, Federici M, Anemona L, Menghini R, Casella S, Cardellini M, Ippoliti A, Mauriello A. Carotid plaque instability is not related to quantity but to elemental composition of calcification. *Nutr Metab Cardiovasc Dis*. 2017;27:768-774. doi: 10.1016/j.numecd.2017.05.006
- Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, Joshi FR, Gallagher FA, Warburton EA, Bennett MR, et al. Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. *Nat Commun*. 2015;6:7495. doi: 10.1038/ncomms8495
- Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, Klutmann S.
 Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med. 2010;51:862-865. doi: 10.2967/jnumed.110.076471
- 27. Morbelli S, Fiz F, Piccardo A, Picori L, Massollo M, Pestarino E, Marini C, Cabria M, Democrito A, Cittadini G, et al. Divergent determinants of 18F–NaF uptake and visible calcium deposition in large arteries: relationship with Framingham risk score. *The International Journal of Cardiovascular Imaging*. 2014;30:439-447. doi: 10.1007/s10554-013-0342-3
- 28. Fiz F, Morbelli S, Piccardo A, Bauckneht M, Ferrarazzo G, Pestarino E, Cabria M, Democrito A, Riondato M, Villavecchia G, et al. ¹⁸F-NaF Uptake by Atherosclerotic Plaque on PET/CT Imaging: Inverse Correlation Between Calcification Density and Mineral Metabolic Activity. *J Nucl Med*. 2015;56:1019-1023. doi: 10.2967/jnumed.115.154229
- 29. Mayer M, Borja AJ, Hancin EC, Auslander T, Revheim ME, Moghbel MC, Werner TJ, Alavi A, Rajapakse CS. Imaging Atherosclerosis by PET, With Emphasis on the Role of

FDG and NaF as Potential Biomarkers for This Disorder. *Front Physiol*. 2020;11:511391. doi: 10.3389/fphys.2020.511391

Bhakta S WE, Evans NR. 18F-Sodium Fluoride Uptake on PET/CT in Symptomatic versus Asymptomatic Atherosclerotic Disease: a Meta-Analysis. PROSPERO: International prospective register of systematic reviews.

www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=42023451363. 2023.

- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi: 10.1136/bmj.n71
- Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). In: Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, ed. Available from www.training.cochrane.org/handbook.: Cochrane; 2023.
- 33. ROBINS-E Development Group (Higgins J MR, Rooney A, Taylor K, Thayer K, Silva R, Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere F, Glenn B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A, McGuinness L, Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E, Savović J, Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K, Stewart T, Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S, Sterne J). Risk Of Bias In Non-randomized Studies - of Exposure (ROBINS-E). Launch version, 20 June 2023. Available from: https://www.riskofbias.info/welcome/robins-e-tool.
- 34. McGrath S, Katzenschlager S, Zimmer AJ, Seitel A, Steele R, Benedetti A. Standard error estimation in meta-analysis of studies reporting medians. *Stat Methods Med Res.* 2023;32:373-388. doi: 10.1177/09622802221139233
- 35. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *Journal of Statistical Software*. 2010;36:1-48. doi: <u>https://doi.org/10.18637/jss.v036.i03</u>
- 36. McGrath S ZX, Katzenschlager S, Ozturk O, Steele R, Benedetti A. *metamedian: Meta-Analysis of Medians; R package version 1.1.0.* 2023.
- 37. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. *Campbell Syst Rev.* 2022;18:e1230. doi: 10.1002/cl2.1230

- 38. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev.* 2016;5:210. doi: 10.1186/s13643-016-0384-4
- Kaczynski J, Sellers S, Seidman MA, Syed M, Dennis M, McNaught G, Jansen M, Semple SI, Alcaide-Corral C, Tavares AAS, et al. (18)F-NaF PET/MRI for Detection of Carotid Atheroma in Acute Neurovascular Syndrome. *Radiology*. 2022;305:137-148. doi: 10.1148/radiol.212283
- Moss A, Daghem M, Tzolos E, Meah MN, Wang K-L, Bularga A, Adamson PD, Kwiecinski J, Fletcher A, Dawson D, et al. Coronary Atherosclerotic Plaque Activity and Future Coronary Events. *JAMA Cardiology*. 2023;8:755-764. doi: 10.1001/jamacardio.2023.1729
- Bucerius J, Hyafil F, Verberne HJ, Slart RHJA, Lindner O, Sciagra R, Agostini D, Übleis C, Gimelli A, Hacker M, on behalf of the Cardiovascular Committee of the European Association of Nuclear M. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. *European Journal of Nuclear Medicine and Molecular Imaging*. 2016;43:780-792. doi: 10.1007/s00259-015-3259-3
- Saba L, Loewe C, Weikert T, Williams MC, Galea N, Budde RPJ, Vliegenthart R, Velthuis BK, Francone M, Bremerich J, et al. State-of-the-art CT and MR imaging and assessment of atherosclerotic carotid artery disease: standardization of scanning protocols and measurements-a consensus document by the European Society of Cardiovascular Radiology (ESCR). *Eur Radiol*. 2023;33:1063-1087. doi: 10.1007/s00330-022-09024-7
- 43. Kaul P, Douglas PS. Atherosclerosis Imaging. *Circulation: Cardiovascular Imaging*.
 2009;2:150-160. doi: doi:10.1161/CIRCIMAGING.109.850263
- Evans NR, Tarkin JM, Le EP, Sriranjan RS, Corovic A, Warburton EA, Rudd JH.
 Integrated cardiovascular assessment of atherosclerosis using PET/MRI. *The British Journal of Radiology*. 2020;93:20190921. doi: 10.1259/bjr.20190921
- McKenney-Drake ML, Moghbel MC, Paydary K, Alloosh M, Houshmand S, Moe S, Salavati A, Sturek JM, Territo PR, Weaver C, et al. (18)F-NaF and (18)F-FDG as molecular probes in the evaluation of atherosclerosis. *Eur J Nucl Med Mol Imaging*. 2018;45:2190-2200. doi: 10.1007/s00259-018-4078-0

- 46. Bing R. SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis. ClinicalTrials.gov. <u>https://clinicaltrials.gov/study/NCT02132026</u>. 2014.
- Montanaro M, Scimeca M, Anemona L, Servadei F, Giacobbi E, Bonfiglio R, Bonanno E, Urbano N, Ippoliti A, Santeusanio G, et al. The Paradox Effect of Calcification in Carotid Atherosclerosis: Microcalcification is Correlated with Plaque Instability. *Int J Mol Sci.* 2021;22. doi: 10.3390/ijms22010395
- Dweck MR, Joshi NV, Jenkins W, Jones C, Chow MWL, Fletcher A, van Beek EJR, Boon NA, Rudd JHF, Newby DE. Assessment of calcification and inflammation with positron emission tomography in aortic stenosis and atherosclerosis. *The Lancet*. 2013;381:S11. doi: 10.1016/S0140-6736(13)60451-1
- Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, Yeoh SE, Wallace W, Salter D, Fletcher AM, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. *Lancet*. 2014;383:705-713. doi: 10.1016/S0140-6736(13)61754-7
- 50. Quirce R, Martinez-Rodriguez I, Banzo I, Jimenez-Bonilla J, Martinez-Amador N, Ibanez-Bravo S, Lopez-Defillo J, Jimenez-Alonso M, Revilla MA, Carril JM. New insight of functional molecular imaging into the atheroma biology: 18F-NaF and 18F-FDG in symptomatic and asymptomatic carotid plaques after recent CVA. Preliminary results. *Clin Physiol Funct Imaging*. 2016;36:499-503. doi: 10.1111/cpf.12254
- 51. Vesey AT, Jenkins WS, Irkle A, Moss A, Sng G, Forsythe RO, Clark T, Roberts G, Fletcher A, Lucatelli C, et al. (18)F-Fluoride and (18)F-Fluorodeoxyglucose Positron Emission Tomography After Transient Ischemic Attack or Minor Ischemic Stroke: Case-Control Study. *Circ Cardiovasc Imaging*. 2017;10:e004976. doi: 10.1161/CIRCIMAGING.116.004976
- 52. Andrews J, Moss A, Doris M, Pawade T, Adamson P, MacNaught G, Lucatelli C, Newby D, Dweck M. 18 18F-flouride pet MR in valvular and coronary heart disease; a pilot investigational study. *Heart*. 2018;104:A12-A12. doi: 10.1136/heartjnl-2018-BCVI.33
- 53. Marchesseau S, Seneviratna A, Sjoholm AT, Qin DL, Ho JXM, Hausenloy DJ, Townsend DW, Richards AM, Totman JJ, Chan MYY. Hybrid PET/CT and PET/MRI imaging of vulnerable coronary plaque and myocardial scar tissue in acute myocardial infarction. *J Nucl Cardiol*. 2018;25:2001-2011. doi: 10.1007/s12350-017-0918-8

- 54. Sood A, JOIS A, Singhal M, Mittal B, Manoj R, Rana N, RAWAT D, Kasinadhuni G, Krisnappa D. Role of ¹⁸F-NaF PET/CT based imaging of atherosclerotic plaques in patients with myocardial infarction and chronic stable angina. *Journal of Nuclear Medicine*. 2018;59:1509-1509.
- Chowdhury MM, Tarkin JM, Albaghdadi MS, Evans NR, Le EPV, Berrett TB, Sadat U, Joshi FR, Warburton EA, Buscombe JR, et al. Vascular Positron Emission Tomography and Restenosis in Symptomatic Peripheral Arterial Disease: A Prospective Clinical Study. *JACC Cardiovasc Imaging*. 2020;13:1008-1017. doi: 10.1016/j.jcmg.2019.03.031
- 56. Evans NR, Tarkin JM, Chowdhury MM, Le EPV, Coughlin PA, Rudd JHF, Warburton EA.
 Dual-Tracer Positron-Emission Tomography for Identification of Culprit Carotid
 Plaques and Pathophysiology In Vivo. *Circ Cardiovasc Imaging*. 2020;13:e009539. doi:
 10.1161/CIRCIMAGING.119.009539
- 57. Cocker MS, Spence JD, Hammond R, Wells G, deKemp RA, Lum C, Adeeko A, Yaffe MJ, Leung E, Hill A, et al. [(18)F]-NaF PET/CT Identifies Active Calcification in Carotid Plaque. *JACC Cardiovasc Imaging*. 2017;10:486-488. doi: 10.1016/j.jcmg.2016.03.005
- 58. Hop H, de Boer SA, Reijrink M, Kamphuisen PW, de Borst MH, Pol RA, Zeebregts CJ, Hillebrands JL, Slart R, Boersma HH, et al. (18)F-sodium fluoride positron emission tomography assessed microcalcifications in culprit and non-culprit human carotid plaques. J Nucl Cardiol. 2019;26:1064-1075. doi: 10.1007/s12350-018-1325-5
- Kim JM, Lee ES, Park KY, Seok JW, Kwon OS. Analysis of (18)F-Fluorodeoxyglucose and (18)F-Fluoride Positron Emission Tomography in Korean Stroke Patients with Carotid Atherosclerosis. J Lipid Atheroscler. 2019;8:232-241. doi: 10.12997/jla.2019.8.2.232
- 60. Mechtouff L, Sigovan M, Douek P, Costes N, Le Bars D, Mansuy A, Haesebaert J, Bani-Sadr A, Tordo J, Feugier P, et al. Simultaneous assessment of microcalcifications and morphological criteria of vulnerability in carotid artery plaque using hybrid (18)F-NaF PET/MRI. J Nucl Cardiol. 2022;29:1064-1074. doi: 10.1007/s12350-020-02400-0

Author	Artic	Arterial	How	Enrolled	Types	Sympto	Time	Compa	Dose	Imaging	Endpoin	Blood	Findings
and Year	le	Territor	was	populat	of	matic	from	rator	of	protocol	t	Pool	
	Туре	y and	the	ion	imagi	patient	onset	popula	NaF		measur	Measure	
		Type of	sympto	demogr	ng	s	of	tion,	injec		е	ment	
		Sympto	matic	aphics -	used	comple	sympt	numbe	ted,				
		matic	disease	number		ting	oms to	r of	Upta				
		Disease	diagno	of		18F-	scan	compar	ke				
			sed?	particip		NaF		ator	time				
				ants,		PET		data					
				mean		imagin		points					
				age and		g (n),		(n)					
				sex		numbe							
						r of							
						sympto							
						matic							
						plaque							
						s							

Table 1 Included study characteristics for studies comparing symptomatic to asymptomatic disease between arteries in the same participant

Dweck ⁴⁸ ,	Abst	Corona	Not	n = 15,	FDG	15, 15	Not	Maxim	Not	Not listed	TBR (no	Not	Increase
2013	ract	ry,	listed	age/sex	and		listed	um	liste		further	listed	d uptake
		myocar		data not	NaF			uptake	d		descript		noted at
		dial		listed	PET-			elsewh			ion)		the
		infarcti			СТ			ere in					culprit
		on						the					lesion
								corona					compar
								ry					ed with
								arteries					the
								, 15					maximu
													m
													uptake
													elsewhe
													re in the
													coronar
													у
													arteries
													(TBR
													median
													1.56

													[IQR
													1.49-
													1.82] vs
													1.23
													[1.15-
													1.48],
													p=0.02)
Joshi ⁴⁹ ,	Pape	Corona	Clinical	n = 40,	FDG	40, 40	Media	Maxim	123	Electrocard	TBRmax	correcte	18F-NaF
2014	r	ry, ST-	guideli	age 62 ±	and		n 8 [3-	um	± 5	iograph-	- ROIs	d for	activity
		elevatio	ne	8 years,	NaF		10]	signal	MBq	gated PET	drawn	blood	in the
		n	criteria	93%	PET-		days	value	, 60	images	around	pool	culprit
		myocar		male	СТ, СТ			of the	± 9	were	all	activity	plaque
		dial			coron			non-	minu	reconstruct	major	in the	was 34%
		infarcti			ary			culprit	tes	ed in	(diamet	superior	higher
		on or			angiog			vessels,		diastole	er >2	vena	than the
		non-ST-			ram,			40			mm)	cava	maximu
		elevatio			coron						epicardi		m
		n			ary						al		activity
		myocar			angiog						vessels		recorde
		dial			ram						on 3		d

infarcti				mm	anywher
on				axial	e else in
				slices	the
				just	coronar
				beyond	У
				the	vasculat
				discerni	ure
				ble	(maximu
				adventit	m TBR
				ial	1.66
				border;	[1.40-
				18F-NaF	2.25] vs
				uptake	1.24
				in the	[1.06-
				culprit	1.38],
				plaque	p<0.000
				was	1)
				compar	
				ed with	
				the	

											highest		
											value in		
											any of		
											the		
											non-		
											culprit		
											vessels		
Quirce ⁵⁰ ,	Shor	Carotid,	Not	n = 9,	FDG +	9,9	Within	Contral	370	beds	TBRmax	SUVmax	Mean
2016	t	stroke	listed	age	NaF		10	ateral	MBq	including	using	in the	TBR was
	Rep	or		range	PET-		days	artery,	, 180	the head	SUVmax	lumen of	2.12 ±
	ort	transie		50-83	СТ			9	minu	and	in the	the	0.44 in
		nt		years,					tes	cervical	plaque	superior	the
		ischemi		88.9%						region		vena	sympto
		c attack		male						were		cava	matic
										acquired at			plaques
										5 min per			and 1.85
										bed. Image			± 0.46 in
										data were			the
										reconstruct			asympto
										ed, and			

										attenuatio			matic (P
										n			= 0.22)
										correction			
										was done			
										after			
										applying			
										iterative			
										reconstruct			
										ion			
										methods			
										with 2			
										iterations			
										and 16			
										subsets.			
Vesey ⁵¹ ,	Раре	Carotid,	Not	n = 26,	FDG +	14, 14	Not	Contral	244.	PET	Three	average	Culprit
2017	r	stroke	listed	demogr	NaF		listed	ateral	5 ±	acquisition	ROIs	of 5 ROIs	2.75
		or		aphic	PET-			artery,	12.6	covering 2	drawn	within	[2.39-
		transie		data	СТ, СТ			14	6	bed	on	the	3.21] vs
		nt		listed	angiog				MBq	positions,	adjacen	lumen of	contrala
				separat	ram				,	15 minutes	t 3-mm	the	teral

ischemi	ely:		64.6	per bed.	axial	superior	2.42
c attack	sympto		± 5.6	PET data	slices. If	vena	[2.02-
	matic		minu	reconstruct	plaque	cava	2.82];
	carotid		tes	ed with	present,		p=0.014
	disease:			ordered	ROIs		for
	n = 18,			subset	centere		log10
	age 71.7			expectatio	d on		transfor
	± 12.3			n	area of		med
	years,			maximizati	highest		distribut
	66.7%			on+point	uptake.		ion of
	male;			spread	lf no		original
	asympt			function	plaque		data
	omatic			modeling+t	present,		
	carotid			ime-of-	uptake		
	disease:			flight; 2	in the		
	n = 8,			iterations	proxima		
	age 66.1			and 21	l 1 cm		
	± 12.5			subsets;	of		
	years,			matrix size	internal		
				200x200; 5	carotid		

				50%						mm full-	artery,		
				male						width half-	just		
										maximum	distal to		
										Gaussian	the		
										smoothing.	bifurcati		
											on was		
											quantifi		
											ed.		
Andrews	Abst	Corona	Clinical	n = 13,	NaF	13, 13	Not	Vessel	Not	PET data	TBRmax	Not	13/13
⁵² , 2018	ract	ry,	+	age/sex	PET-		listed	proxim	liste	acquired in	- focal	listed	patients
		myocar	imaging	data not	MRI,			al to	d	list mode,	18F-NaF		with MI
		dial		listed	MR			culprit		Dixon	uptake		had
		infarcti			angiog			plaque,		attenuatio	in		focal
		on			ram			13		n	culprit		18F-NaF
										correction	vessel		uptake
										technique			in the
													culprit
													vessel
													with a
													TBR max

													greater
													than the
													proximal
													referent
													vessel
													(TBRmax
													1.64±0.4
													7 vs
													1.16±0.2
													6,
													p=0.004
)
Marches	Раре	Corona	Clinical	n = 10,	NaF	8, 8	Media	Non-	2.95	10 minute	TBRmax	Mean	TBR of
seau ⁵³ ,	r	ry, ST-	guideli	age 48 ±	PET-		n 13.5	culprit	±	acquisition,	- ratio	SUV of	the
2018		elevatio	ne	7 years,	MRI +		(range	plaque	0.21	one bed	of the	the	culprit
		n	criteria	90%	PET-		9-24)	s, 25	mCi,	position	calcium	correspo	lesions
		myocar		male	CT,		days		108	centered	region	nding	was
		dial			cardia				± 21	over the	maximu	vessel	significa
		infarcti			c MRI,				minu	heart;	m SUV	minus	ntly
		on			СТ				tes	reconstruct	over the	the	higher

		coron			ed using an	corresp	previousl	than the
		ary			iterative	onding	у	TBR for
		artery			reconstruct	vessel	selected	non-
		calciu			ion (3	(excludi	ROI	culprit
		m			iterations,	ng the		lesions
		score			21 subsets,	calcium		with an
		scan			2 mm pixel	ROIs)		average
					size, 2 mm	mean		value of
					FWHM	SUV		2.11 for
					Gaussian			culprit
					filter), with			(±0.42)
					attenuatio			and 1.36
					n and			(±0.30)
					scatter			for non-
					corrections			culprit
					included as			(P value
					well as			<0.001)
					Time of			
					Flight and			
					Point			

										Spread Function correction			
Sood ⁵⁴ ,	Abst	Corona	Clinical	n = 24,	NaF	24, 24	Not	Non-	3-5	acquired in	TBRmax	Not	The
2018	ract	ry,	guideli	age/sex	PET-		listed	culprit	mCi,	list mode	from	listed	differen
		myocar	ne	data not	СТ, СТ			vessels,	45		SUVmax		ce in
		dial	criteria	listed	coron			24	minu		of		median
		infarcti			ary				tes		vessels		TBR of
		on			angiog								culprit
					ram								vessels
													(1.46,
													IQR:
													1.29-
													1.73)
													and
													non-
													culprit
													vessels
													(0.99,
													IQR:

													0.80-
													1.02)
													was
													statistic
													ally
													significa
													nt (p-
													value
													<0.0001)
Chowdh	Раре	Superfi	Clinical	n = 50,	FDG	40, 40	Not	Contral	Mea	PET data	TBRmax	5 ROIs	Median
ury ⁵⁵ ,	r	cial	+	median	and		applica	ateral	n	acquired	- ROIs	drawn in	baseline
2020		femoral	imaging	age 70	NaF		ble -	artery,	401.	from iliac	placed	the	18F-NaF
		artery,		[65-78]	PET-		partici	40	4	crest to	on	center of	TBRmax
		periphe		years,	СТ, СТ		pants		MBq	tibial	adjacen	the	was 1.78
		ral		66%	angiog		includ		, 60	plateau, 4	t axial	common	(IQR:
		vascula		male	ram		ed		minu	minute	images,	femoral	1.62 to
		r					with		tes	acquisition	SUVmax	vein	2.50);
		disease					interm			per bed	per slice		1.54
		(interm					ittent			position	recorde		(IQR:
		ittent									d		1.36 to

		claudic					claudic						1.72) in
		ation or					ation						the
		critical											contrala
		limb											teral
		ischemi											(untreat
		a)											ed,
													asympto
													matic)
													limb, no
													p value
													reporte
													d
Evans ⁵⁶ ,	Pape	Carotid,	Clinical	n = 31,	FDG	26, 26	8.5 ±	Contral	125	ROIs drawn	MDS	mid-	NaF
2020	r	stroke	+	age 74.8	and		4.2	ateral	MBq	along the	TBRmax	luminal	uptake
			imaging	± 9.7	NaF		days to	artery,	, 60	common	: MDS	ROIs in	was
				years,	PET-		initial	26	minu	carotid and	uses	the	higher in
				69.2%	СТ, СТ		scan,		tes	internal	most	jugular	culprit
				male	angiog		53.8%			carotid	disease	vein over	plaques
					ram		had			artery to	d 9 mm,	5	than
							NaF			encompass	based	contiguo	nonculp

			PET		the region	on	us 3 mm	rit
			first,		0.9 cm	tracer	slices	plaques
			media		proximal	uptake		when
			n 1		and 3 cm	3		consider
			[IQR		distal to	contigu		ing MDS
			1.75]		the carotid	ous		TBRmax
			days		bifurcation	axial		- mean
			betwe			slices		2.85 +/-
			en NaF			where		1.15 vs
			and			the		2.34 +/-
			FDG			central		0.64,
			scans			ROI has		p<0.01
						the		
						highest		
						uptake		
						within		
						the		
						artery		

Kaczynsk	Раре	Carotid,	Clinical	n = 110,	NaF	110,	Not	Contral	125	PET data	TBRmax	averaged	Culprit
i ³⁹ , 2022	r	stroke,	+	age 68 ±	PET-	110	listed	ateral	MBq	obtained	- uptake	from 3	vessels
		transie	imaging	10	MRI,			artery,	, 60	using list-	measur	ROIs	had a
		nt		years,	MR			110	minu	mode	ed in a	within	higher
		ischemi		64%	angiog				tes	acquisition	spherica	the	18F-NaF
		c attack		male	ram					s with two	Ινοι	brachioc	uptake
		or								15-min	centere	ephalic	than
		amauro								beds	d on the	or	non-
		sis								positions	most	internal	culprit
		fugax								covering	severe	jugular	vessels
										the carotid	stenosis	veins	(TBRmax
										arteries			1.38
										(aortic arch			[1.12,
										to skull			1.82]
										base).			versus
										Images			1.26
										reconstruct			[0.99,
										ed with			1.66],
										corrections			p=.04)
										applied for			

			attenuatio	
			n, dead	
			time,	
			scatter and	
			random	
			coincidenc	
			es (matrix	
			size	
			256x256,	
			ordered	
			subset	
			expectatio	
			n	
			maximizati	
			on	
			reconstruct	
			ion with	
			point	
			spread	
			function	

					modelling,		
					3		
					iterations,		
					21 subsets,		
					2mm		
					Gaussian		
					filtration)		

Author	Arti	Arterial	How	Particip	Types	Sympto	Time	Compara	Dose	PET	Endpo	Blood	Findings
, Year	cle	Territor	sympto	ant	of	matic	from	tor	of NaF	Imaging	int	Pool	
	Тур	у, Туре	matic	demogr	imagi	patient	onset	populati	injecte	protoco	measu	Measur	
	е	of	disease	aphics -	ng	s	of	on,	d <i>,</i>	I	re	ement	
		Sympto	was	number	used	comple	sympt	number	Uptak				
		matic	diagnos	of		ting	oms	of	e time				
		Disease	ed	particip		18F-	to	compara					
				ants,		NaF	scan	tor data					
				mean		PET		points					
				age and		imaging		(n)					
				sex		(n) <i>,</i>							
						number							
						of							
						sympto							
						matic							
						plaques							

Table 2 Included study characteristics for studies comparing symptomatic to asymptomatic disease within and between participants

Irkle ²⁵ ,	Рар	Carotid,	Not	n = 7,	NaF	5, 5	16.4 ±	PET-	Not	PET	"Mean	Not	Individual
2015	er	stroke	listed	age 68.9	PET-		8.0	positive	listed	scannin	of	listed	participant
		or		± 13.5	СТ		days	regions in		g	Max"		data
		transie		years,				asympto		perform	TBR		reported,
		nt		57.1%				matic		ed for			and
		ischemi		male				participa		75			converted
		c attack						nts, 2		minutes			to
										followin			median/inte
										g tracer			rquartile
										injectio			range:
										n			symptomati
													c disease
													2.48 [1.80-
													3.33] vs
													asymptomat
													ic disease
													2.41 [2.32-
													2.49] <i>,</i> no p
													value.

Cocker ⁵	Sho	Carotid,	Not	n = 11,	NaF	9, 9	Not	Contralat	3	PET/CT	TBRm	Normali	Plaque
⁷ , 2017	rt	stroke	listed	age 69 ±	PET-		listed	eral	MBq/k	imaging	ax -	zed to	associated
	Rep	or		5 years,	СТ, СТ			artery or	g, 60	was	maxim	mean	with
	ort	transie		72.7%	angio			asympto	minute	perform	um	SUV in	symptoms
		nt		male	gram			matic	S	ed,	18F-	internal	had
		ischemi						carotid		followe	NaF	jugular	evidence for
		c attack						arteries,		d by CT	activit	vein	greater 18F-
								11		angiogr	y for		NaF uptake
										aphy	each		than plaque
											plaqu		not
											е		associated
													with
													symptoms
													(TBRmax:
													3.75 ± 1.10
													vs. 2.79 ±
													0.60; p =
													0.04)

Hop ⁵⁸ ,	Рар	Carotid,	Clinical	n = 23,	NaF	17, 17	21 ±	Endarter	49.4 ±	MicroPE	%Inc/g	N/A	Average
2019	er	stroke	+	median	micro		14	ectomy	7.2	т	_		18F-NaF
			imaging	age 72	PET,		days	specimen	MBq	emissio	Perce		uptake was
				[61-75]	micro			s from	(incub	n scan	ntage		similar in
				years,	СТ			non-	ated),	for 30	uptak		culprit and
				85%				culprit	60	minutes	e of		non-culprit
				male				plaques,	minute	,	total		carotid
								6	S	reconstr	incuba		plaques
										ucted	tion		(median
										using	dose		2.32 %Inc/g
										OSEM2	per		[IQR 1.98 to
										D (4	gram		2.81] vs.
										iteratio	of		median 2.35
										ns and	tissue		%Inc/g [IQR
										16	(%Inc/		1.77 to
										subsets)	g).		3.00], p =
										, after			0.916)
										being			
										normali			
										zed and			

										correcte			
										d for			
										attenua			
										tion and			
										decay of			
										radioact			
										ivity.			
Kim ⁵⁹ ,	Рар	Carotid,	Clinical	n = 18,	FDG	10, 10	Media	Contralat	259-	PET	NaF	SUV of	NaF TBRmax
2019	er	stroke	+	demogr	and		n 17	eral	370	images	TBRm	aortic	at the
		or	imaging	aphic	NaF		(rang	artery or	MBq,	acquire	ax at	blood	largest
		transie		data	PET-		e 3-	asympto	60	d at 5	the		atheroma
		nt		listed	СТ, СТ		37)	matic	minute	min/be	largest		segment in
		ischemi		separat	angio		days	carotid	S	d for	athero		symptomati
		c attack		ely:	gram			arteries		the	ma		c vs
				sympto				in those		head	segme		asymptomat
				matic				with an		and 1	nt		ic plaques:
				group: n				alternativ		min/be			1.53 ± 0.54
				= 10,				e cause		d from			vs 1.39 ±
				age 72.9						the skull			

				± 8.2				of stroke,		base to			0.45, p =
				years,				26		the			0.37
				50%						proxima			
				male;						l thigh			
				asympto									
				matic									
				group: n									
				= 8, age									
				77.1 ±									
				10.9									
				years,									
				50%									
				male									
Mechto	Рар	Carotid,	Not	n = 12,	NaF	6, 6	9.2 ±	Contralat	3	15	TBRm	mean of	18F-NaF
uff ⁶⁰ ,	er	stroke	listed	age 68 ±	PET-		6.2	eral	MBq/k	minute	ах	five	uptake was
2022		or		10	MRI,		days	artery	g, 60	PET	measu	ROIs in	higher in
		transie		years,	MR			and	minute	acquisiti	red	the mid	culprit
		nt		75%	angio			carotid	S	on	using	lumen	plaques
		ischemi		male	gram			arteries			3 ROIs	of the	compared
		c attack						of			center	superior	to

				asympto		ed on	vena	nonculprit
				matic		the	cava	plaques
				control		area		(median TBR
				participa		of		2.6 [2.2-2.8]
				nts, 18		highes		vs 1.7 [1.3-
						t		2.2]; P =
						uptak		0.03)
						e in		
						the		
						plaqu		
						е		

medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24303229; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Embase <1996 to 2023 Week 30>

Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions <1946 to August 02, 2023>

- 1 (18F* or NaF or \$F-NaF*).ti,ab.
- (PET or positron*).ti,ab. 2
- 3 (athero* or acute or microcalcif* or plaque).ti,ab.
- 4 (culprit or symptom* or active).ti,ab.
- 5 1 and 2 and 3 and 4
- 6 (editorial* or case report* or review* or meta-analysis).pt.
- 7 5 not 6

Figure 1 Search strategy performed for systematic review and meta-analysis

medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24303229; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .




Figure 2 Funnel plot of studies included in Table 1

medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24303229; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .




Figure 3 Funnel plot of studies included in Table 2

medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24303229; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .




Figure 4 PRISMA diagram of systematic review search synthesis

Author and Year	Radiotracer Uptake	Weight and SMD [95% CI]
Carotid Arteries		
Quirce et al., 2016	F	6.71% 0.27 [-0.15, 0.69
Vesey et al., 2017	FI	6.49% 0.35 [-0.08, 0.77]
Evans et al., 2020	•	5.06% 0.51 [0.00, 1.02
Kaczynski et al., 2022		16.12% 0.14 [-0.01, 0.30
Random effects model - all carotid artery studies Heterogeneity: Q = 3.00, df = 3, p = 0.39, l ² = 19.87%, τ^2 = 0.01		0.23 [0.05, 0.41
Coronary Arteries		
Dweck et al., 2013	F ₽ 1	16.18% 0.34 [0.19, 0.49
Joshi et al., 2014	⊢	13.23% 0.58 [0.36, 0.79
Andrews et al., 2018	⊢ I	10.23% 0.48 [0.19, 0.77
Marchesseau et al., 2018	F	9.48% 0.75 [0.44, 1.06
Sood et al., 2018	⊢	8.55% 0.55 [0.21, 0.90
Random effects model - all coronary artery studies Heterogeneity: Q = 7.23, df = 4, p = 0.12, l ² = 45.30%, τ^2 = 0.01		0.51 [0.36, 0.66
Peripheral Arteries		
Chowdhury et al., 2020	۱ <u>ــــ</u> ۱	7.95% 0.46 [0.09, 0.82
Random Effects Model for all studies Heterogeneity: Q = 19.89, df = 9, p = 0.019, I^2 = 54.07%, τ^2 = 0.02 Test for differences between arterial territory subgroups: Q _M = 5.02, df = 2, p = 0.08		100% 0.42 [0.29, 0.56
Test for overall effect: Z = 6.36 (p <0.001)		
	-0.25 0 0.25 0.5 0.75 1	1.25
	Standardised Mean Difference	

Figure 5 Forest Plot of included studies summarising data comparing symptomatic and asymptomatic atherosclerotic disease within individuals. SMD = standardized mean difference, CI = confidence intervals





Figure 6 Forest Plot of included studies summarizing data comparing symptomatic and asymptomatic atherosclerotic disease within individuals. SMD = standardized mean difference, CI = confidence intervals medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24303229; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .



Supplementary Figure 1 - Summary plot of Risk of Bias assessment using ROBINS-E (Risk Of Bias In Non-randomized Studies - of Exposures) tool